Cargando…
Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?
Patients classified as idiopathic pulmonary arterial hypertension (defined as Group 1 on European Respiratory Society (ERS)/European Cardiac Society (ESC) criteria) may have evidence of minor co-existing lung disease on thoracic computed tomography. We hypothesised that these idiopathic pulmonary ar...
Autores principales: | Peacock, Andrew J., Ling, Yi, Johnson, Martin K., Kiely, David G., Condliffe, Robin, Elliot, Charlie A., Gibbs, J. Simon R., Howard, Luke S., Pepke-Zaba, Joanna, Sheares, Karen K.K., Corris, Paul A., Fisher, Andrew J., Lordan, James L., Gaine, Sean, Coghlan, J. Gerry, Wort, S. John, Gatzoulis, Michael A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132795/ https://www.ncbi.nlm.nih.gov/pubmed/32284847 http://dx.doi.org/10.1177/2045894020914851 |
Ejemplares similares
-
Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension
por: Rhodes, Christopher J., et al.
Publicado: (2017) -
Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study
por: Karia, Nina, et al.
Publicado: (2023) -
EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study
por: Lewis, Robert A., et al.
Publicado: (2021) -
Lifting the fog in intermediate-risk (submassive) PE: full dose, low dose, or no thrombolysis?
por: Bhamani, Amyn, et al.
Publicado: (2019) -
Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy
por: Wilkins, Martin R., et al.
Publicado: (2021)